Company: BNBX
Filing Date: 2025-01-10
Form Type: S-1/A
Source: 0001104659-25-002521
Chunk: 9

Company: BNB PLUS CORP.
Filing Date: 2025-01-10
Form: S-1/A
Chunk 9
---
 easily chemically modified to suit specific customer applications. In addition, the        
 LineaDNA platform can produce a wide range of complex DNA sequences that are difficult to produce via plasmid-based DNA production       
 platforms. These complex sequences include inverted terminal repeats and long homopolymers such as polyadenylation sequences (poly       
 (A) tail) important for gene therapy and mRNA therapies, respectively.                                                                   |

Preclinical studies conducted by the Company
have shown that LineaDNA is substitutable for plasmid DNA in numerous nucleic acid-based therapies, including:

| · | DNA vaccines; |

| · | DNA templates to produce          
 RNA, including mRNA therapeutics; |

| · | adoptive cell therapy (CAR-T) 
 manufacturing; and            |

| · | homology-directed repair     
 (HDR)-mediated gene editing. |

Further, we believe that LineaDNA is also
substitutable for plasmid DNA in the following nucleic acid-based therapies:

| · | viral vector manufacturing            
 for in vivo and ex vivo gene editing; |

| · | clustered regularly interspaced                      
 short palindromic repeats-mediated gene therapy; and |

| · | non-viral gene therapy. |

Linea IVT Platform

The number of mRNA therapies under development
is growing at a rapid rate, thanks in part to the success of the mRNA COVID-19 vaccines. mRNA therapeutics are produced via a process
called in vitro transcription (“IVT”) that requires DNA as a starting material. As of the third quarter of calendar
2024, there were over 450 mRNA therapies under development, with the majority of these therapies (67%) in the preclinical stage (Source:
ASGCT Gene, Cell & RNA Therapy Landscape: Q3 2024 Quarterly Report). The Company believes that the mRNA market is in a nascent
stage that represents a large growth opportunity for the Company via the production and supply of DNA critical starting materials and
RNAP to produce mRNA therapies.

In August 2022, the Company launched
DNA IVT templates manufactured via its LineaDNA platform that have resulted in evaluations of the Company’s IVT templates by numerous
therapeutic developers and CDMOs in the United States and the Asia-Pacific. In addition, the Company’s IVT templates are currently
under late-stage evaluations by two therapeutic developers and one CDMO for use as DNA templates for the production of mRNA intended
for clinical use in calendar year 2025. However, there can be no assurance that